Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
Although the majority of primary HIV-1 variants can be neutralized by broadly neutralizing antibodies such as b12, 2G12, 2F5 and 4E10, resistance to these antibodies has been reported as well. The ability of the broadly neutralizing antibodies to inhibit a variety of viruses suggests that their epitopes are conserved and escape from these antibodies may thus come at a cost to viral fitness. Here we demonstrate that resistance to broadly neutralizing antibodies was in general not associated with a reduced replicative capacity of the virus in vitro. This indicates that loss of replicative capacity due to escape from broadly neutralizing antibodies may be limited.
Quakkelaar
Esther D
ED
Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, Department of Clinical Viro-Immunology, Center for Infection and Immunity Amsterdam, University of Amsterdam, Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands.
Bunnik
Evelien M
EM
van Alphen
Floris P J
FP
Boeser-Nunnink
Brigitte D M
BD
van Nuenen
Ad C
AC
Schuitemaker
Hanneke
H
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D024882:Drug Resistance, Viral; D000939:Epitopes / Q000276:immunology; D014644:Genetic Variation; D015483:HIV Antibodies / Q000276:immunology / Q000494:pharmacology*; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000472:pathogenicity* / Q000502:physiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009500:Neutralization Tests; D014774:Virulence / Q000235:genetics; D014779:Virus Replication
D000911:Antibodies, Monoclonal; D000939:Epitopes; D015483:HIV Antibodies